Home / Stocks / SRPT

Sarepta Therapeutics (SRPT, Biotechnology) Stock Valuation & Fair Value Trading above fair value

Sarepta Therapeutics (SRPT, Biotechnology) trades at a blended P/E of 77.3, about 39% above its historical normal valuation, with a forward growth estimate of 63.0% and a PEG of 1.23. Analysts' one-year estimates have been hit 9% of the time. Priced at its historical normal P/E of 55.8 on the same blended earnings, the 2026-09-18 close of $20.11 corresponds to about $14.50 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
77.3
Normal P/E
55.8
PEG
1.23
Fwd growth
63.0%
Div yield
0.0%
RSI (14)
44.4
Neutral
Technical context
  • Price $18.95 at the 2026-09-23 close, 9.1% below the 20-day average ($20.85) and 2.0% above the 50-day ($18.58).
  • RSI (14) at 44.4.
  • 52-week range $14.86 to $24.45: the price is 22.5% below the high and 27.5% above the low.

The Street vs SeerForecast

Wall Street's mean price target for SRPT is $21.86 across 22 analysts, 15.4% above the current price. The average analyst rating is Hold. Our SeerForecast read of the same stock, formed without analyst targets: trading above fair value. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer published no valuation rating on 2026-07-31, and rates it trading above fair value as of 2026-09-21.

Price and rating by weekClose moved +35.3 percent from 2026-07-31 to 2026-09-21, with 2 rating changes over 18 recorded weeks.2026-07-31: No P/E valuation, close 14.86 (recalculated)2026-08-03: No P/E valuation, close 14.862026-08-07: No P/E valuation, close 16.78 (recalculated)2026-08-10: No P/E valuation, close 16.782026-08-14: No P/E valuation, close 18.10 (recalculated)2026-08-17: No P/E valuation, close 18.102026-08-21: No P/E valuation, close 18.79 (recalculated)2026-08-24: No P/E valuation, close 18.792026-08-27: No P/E valuation, close 21.59 (recalculated)2026-08-28: No P/E valuation, close 20.86 (recalculated)2026-08-30: No P/E valuation, close 20.86 (recalculated)2026-08-31: No P/E valuation, close 20.862026-09-05: No P/E valuation, close 22.50 (recalculated)2026-09-07: No P/E valuation, close 22.502026-09-12: No P/E valuation, close 20.45 (recalculated)2026-09-14: Significantly overvalued, close 20.452026-09-19: Significantly overvalued, close 20.11 (recalculated)2026-09-21: Trading above fair value, close 20.11$16$18$20$22Jul 31Aug 13Aug 26Sep 8Sep 21
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 0.0not availableNo P/E valuation
2026-09-05P/E 0.0not availableNo P/E valuation
2026-09-14P/E 2,079.2>500%Significantly overvalued
2026-09-21P/E 77.3+39%Trading above fair value ← now

Frequently asked questions

Is Sarepta Therapeutics stock overvalued?

At a blended P/E of 77.3 versus its historical normal P/E of 55.8, Sarepta Therapeutics trades about 39% above its typical valuation, with a PEG of 1.23 on 63.0% forward growth. tickerseer currently rates it trading above fair value.

What is Sarepta Therapeutics's fair value and PEG?

Sarepta Therapeutics trades at a blended P/E of 77.3 against a historical normal P/E of 55.8, a PEG of 1.23, and a forward growth estimate of 63.0%. Priced at its historical normal P/E of 55.8 on the same blended earnings, the 2026-09-18 close of $20.11 corresponds to about $14.50 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Sarepta Therapeutics changed?

tickerseer published no valuation rating on 2026-07-31, and rates it trading above fair value as of 2026-09-21.

What is the analyst price target for Sarepta Therapeutics?

The mean Wall Street price target for Sarepta Therapeutics is $21.86 across 22 analysts, 15.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track SRPT free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.